{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:58:46Z","timestamp":1781272726397,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adults aged \u226565 years, adults with certain underlying medical conditions, and persons experiencing homelessness are at increased risk for invasive pneumococcal disease (IPD). Two new pneumococcal conjugate vaccines, 15-valent pneumococcal conjugate vaccine (PCV15) and 20-valent pneumococcal conjugate vaccine (PCV20), were recently approved for use in US adults. We describe the epidemiology of IPD among Alaska adults and estimate the proportion of IPD cases potentially preventable by new vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used statewide, laboratory-based surveillance data to calculate and compare IPD incidence rates and 95% confidence intervals (CIs) among Alaska adults aged \u226518 years during 2011\u20132020 and estimate the proportion of IPD cases that were caused by serotypes in PCV15 and PCV20.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During 2011\u20132020, 1164 IPD cases were reported among Alaska adults for an average annual incidence of 21.3 cases per 100 000 adults per year (95% CI, 20.1\u201322.5). Incidence increased significantly during the study period (P &amp;lt; .01). IPD incidence among Alaska Native adults was 4.7 times higher than among non-Alaska Native adults (95% CI, 4.2\u20135.2). Among adults experiencing homelessness in Anchorage, IPD incidence was 72 times higher than in the general adult population (95% CI, 59\u201389). Overall, 1032 (89%) Alaska adults with IPD had an indication for pneumococcal vaccine according to updated vaccination guidelines; 456 (39%) and 700 (60%) cases were caused by serotypes in PCV15 and PCV20, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Use of PCV15 and PCV20 could substantially reduce IPD among adults in Alaska, including Alaska Native adults and adults experiencing homelessness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad597","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T12:07:27Z","timestamp":1696075647000},"page":"172-178","source":"Crossref","is-referenced-by-count":19,"title":["Invasive Pneumococcal Disease and Potential Impact of Pneumococcal Conjugate Vaccines Among Adults, Including Persons Experiencing Homelessness\u2014Alaska, 2011\u20132020"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-5304","authenticated-orcid":false,"given":"Jonathan","family":"Steinberg","sequence":"first","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S","family":"Bressler","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Orell","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail C","family":"Thompson","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kretz","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa L","family":"Reasonover","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bruden","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Bruce","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[{"name":"Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Anchorage, Alaska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"2024012801060463400_ciad597-B1","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995\u20131998","volume":"285","author":"Robinson","year":"2001","journal-title":"JAMA"},{"key":"2024012801060463400_ciad597-B3","first-page":"255","volume-title":"Epidemiology and prevention of vaccine-preventable diseases","author":"Gierke","year":"2021"},{"key":"2024012801060463400_ciad597-B4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.5588\/ijtld.13.0270","article-title":"Tuberculosis among the homeless, United States, 1994\u20132010","volume":"17","author":"Bamrah","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801060463400_ciad597-B5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3201\/eid2507.181261","article-title":"Respiratory syncytial virus infection in homeless populations, Washington, USA","volume":"25","author":"Boonyaratanakornkit","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024012801060463400_ciad597-B6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/cix921","article-title":"Outbreak of invasive infections from subtype emm26.3 group A streptococcus among homeless adults\u2014Anchorage, Alaska, 2016\u20132017","volume":"66","author":"Mosites","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024012801060463400_ciad597-B7","doi-asserted-by":"crossref","first-page":"e7255","DOI":"10.1371\/journal.pone.0007255","article-title":"Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto","volume":"4","author":"Plevneshi","year":"2009","journal-title":"PLoS One"},{"key":"2024012801060463400_ciad597-B8","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3201\/eid2510.181408","article-title":"Risk for invasive streptococcal infections among adults experiencing homelessness, Anchorage, Alaska, USA, 2002\u20132015","volume":"25","author":"Mosites","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024012801060463400_ciad597-B9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz362","article-title":"Homelessness in adults with invasive pneumococcal disease in Calgary, Canada","volume":"6","author":"Lemay","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024012801060463400_ciad597-B10","first-page":"1","article-title":"Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Advisory Committee on Immunization Practices","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein\u2013polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"2024012801060463400_ciad597-B12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"2024012801060463400_ciad597-B13","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"key":"2024012801060463400_ciad597-B14","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2005.08.100","article-title":"Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska natives: progress towards elimination of a health disparity","volume":"23","author":"Hennessy","year":"2005","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B15","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Pekka Nuorti","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Impact of 13-valent pneumococcal conjugate vaccine used in children on invasive pneumococcal disease in children and adults in the United States: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2024012801060463400_ciad597-B17","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/cid\/ciz739","article-title":"Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions\u2014United States","volume":"70","author":"Ahmed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024012801060463400_ciad597-B18","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.vaccine.2015.07.080","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska","volume":"33","author":"Bruce","year":"2015","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B19","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"2024012801060463400_ciad597-B22","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B23","author":"Alaska Department of Labor and Workforce Development"},{"key":"2024012801060463400_ciad597-B24","author":"US Department of Housing and Urban Development"},{"key":"2024012801060463400_ciad597-B25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/infdis\/170.2.368","article-title":"The epidemiology of invasive pneumococcal disease in Alaska, 1986\u20131990: ethnic differences and opportunities for prevention","volume":"170","author":"Davidson","year":"1994","journal-title":"J Infect Dis"},{"key":"2024012801060463400_ciad597-B26","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.vaccine.2006.11.065","article-title":"Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults","volume":"25","author":"Singleton","year":"2007","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14745\/ccdr.v44i12a02","article-title":"Outbreak of invasive Streptococcus pneumoniae among an inner-city population in Victoria, British Columbia, 2016\u20132017","volume":"44","author":"McKee","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2024012801060463400_ciad597-B28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciu366","article-title":"Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009\u20132011","volume":"59","author":"Schillberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024012801060463400_ciad597-B29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/infdis\/jiaa501","article-title":"Upsurge of conjugate vaccine serotype 4 invasive pneumococcal disease clusters among adults experiencing homelessness in California, Colorado, and New Mexico","volume":"223","author":"Beall","year":"2020","journal-title":"J Infect Dis"},{"key":"2024012801060463400_ciad597-B30","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.meegid.2011.08.016","article-title":"Population structure of hyperinvasive serotype 12F, clonal complex 218 Streptococcus pneumoniae revealed by multilocus boxB sequence typing","volume":"11","author":"Rakov","year":"2011","journal-title":"Infect Genet Evol"},{"key":"2024012801060463400_ciad597-B31","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.vaccine.2022.04.022","article-title":"Strategies to improve vaccination rates in people who are homeless: a systematic review","volume":"40","author":"McKosker","year":"2022","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/01.inf.0000220231.79968.f6","article-title":"Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis","volume":"25","author":"Shouval","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2024012801060463400_ciad597-B33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJM199409083311004","article-title":"An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail","volume":"331","author":"Hoge","year":"1994","journal-title":"N Engl J Med"},{"key":"2024012801060463400_ciad597-B34","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.vaccine.2006.09.003","article-title":"Changing epidemiology of invasive pneumococcal disease in central Australia prior to conjugate vaccine: a 16-year study","volume":"25","author":"Torzillo","year":"2007","journal-title":"Vaccine"},{"key":"2024012801060463400_ciad597-B35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1017\/S0950268818002133","article-title":"Local outbreak of Streptococcus pneumoniae serotype 12F caused high morbidity and mortality among children and adults","volume":"146","author":"Ikuse","year":"2018","journal-title":"Epidemiol Infect"},{"key":"2024012801060463400_ciad597-B36","first-page":"72","article-title":"Outbreak of invasive pneumococcal disease \u2014Alaska, 2003\u20132004","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024012801060463400_ciad597-B37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1128\/JCM.02880-12","article-title":"Molecular characterization of Streptococcus pneumoniae serotype 12F isolates associated with rural community outbreaks in Alaska","volume":"51","author":"Zulz","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2024012801060463400_ciad597-B38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3201\/eid2301.160897","article-title":"Increased invasive pneumococcal disease, North East England, UK","volume":"23","author":"Houseman","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"2024012801060463400_ciad597-B39","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/aje\/kwab051","article-title":"Data sources that enumerate people experiencing homelessness in the United States: opportunities and challenges for epidemiologic research","volume":"190","author":"Mosites","year":"2021","journal-title":"Am J Epidemiol"},{"key":"2024012801060463400_ciad597-B40","first-page":"1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad597\/52108444\/ciad597.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/1\/172\/56439043\/ciad597.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/1\/172\/56439043\/ciad597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T01:06:26Z","timestamp":1706403986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/1\/172\/7287984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,3]]},"published-print":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad597","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2023,10,3]]}}}